| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56b90d17de0eceddc446d5629249e81a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f681d284cc209fca806ef4bf5ac9f64c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B64C2201-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B64U2101-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B64C39-024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H04N7-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G08B13-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H04N7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B64C39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G08B13-196 |
| filingDate |
2018-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f25ae80df8043cc7701a11851b2f2e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f677611470ee2237f879cf7279ec11fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_074a3e79acc48c2718c5942bb741940c |
| publicationDate |
2020-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10614684-B2 |
| titleOfInvention |
Treatment of kidney diseases associated with elevated AVP |
| abstract |
Disclosed are methods for treating kidney disease including autosomal dominant polycystic kidney disease (ADPKD) in a subject, comprising the step of administering to the subject a composition comprising a therapeutically effective amount of ticagrelor or a derivative thereof, thereby treating ADPKD. Disclosed are methods of decreasing arginine vasopressin (AVP) production in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production. Disclosed are methods for treating dilutional hyponatremia in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023057879-A1 |
| priorityDate |
2017-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |